Ingenza is delighted to announce the appointment of Masha Kononov to head up the company’s business development activities in North America. Masha will commence her new full-time position at the end of October, joining the Ingenza team at the Recent…
Ingenza is pleased to welcome Steve Jones as he takes on the role of Chief Financial Officer (CFO), effective immediately. Steve has over 25 years of industry experience and know-how, after holding several senior finance roles across a wide range of…
Edinburgh-based Ingenza, a pioneer in engineering biology, is delighted to celebrate its 20 year anniversary this month. The milestone will be marked with an event on the 20th of April for esteemed colleagues and guests, providing an opportunity to reflect on the…
Ingenza is excited to welcome Dr Mark Chadwick to the team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position at Ingenza, acquired over 30 years from a variety of roles within small growth companies,…
Edinburgh-based Ingenza, a pioneer in engineering biology, is pleased to announce the appointment of Dr Ian Shott CBE, FREng to the board as Executive Chairman. Ian joins Ingenza with over 35 years of experience in the global life science and biotechnology…
Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia. Amplifica has partnered with Ingenza to advance the development of its…
Ingenza has delivered a new, proprietary biomanufacturing process for human recombinant factor VIII (rhFVIII) to Scottish biotechnology company ProFactor Pharma Ltd (PFP), which will considerably increase global access to low-cost treatment for haemophilia A. The novel bioprocess underpins PFP’s recent…
Jul 5, 2022 – The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with a consortium of research and technological institutions to develop a novel vaccine to provide protection against COVID-19 caused by current and future SARS-CoV-2 variants, as well as…
Biotechnology company Ingenza is delighted to announce that its recent partnership with Johnson Matthey has been selected to receive vital funding of £441,632.88 from the Department of Business, Energy and Industrial Strategy as part of the £1 billion fund from the…
Biotechnology company Ingenza is excited to report the successful conclusion to its recent six-month project with Johnson Matthey, a speciality chemicals and sustainable technologies supplier. Together, the companies have developed new, efficient approaches for the production of industrially-relevant enzymes –…